Human CXCL9 ELISA kit (4X96T)
- Known as:
- Human CXCL9 Enzyme-linked immunosorbent assay test reagent (4X96T)
- Catalog number:
- lf-ek50570
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Abfrontier
- Gene target:
- Human CXCL9 ELISA kit (4X96T)
Related genes to: Human CXCL9 ELISA kit (4X96T)
- Gene:
- CXCL9 NIH gene
- Name:
- C-X-C motif chemokine ligand 9
- Previous symbol:
- CMK, MIG
- Synonyms:
- SCYB9, Humig, crg-10
- Chromosome:
- 4q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 1996-05-28
- Date modifiied:
- 2016-10-05
Related products to: Human CXCL9 ELISA kit (4X96T)
Related articles to: Human CXCL9 ELISA kit (4X96T)
- Neutrophil extracellular traps (NETs) are chromatin-based structures released by activated neutrophils that are associated with microvascular thrombosis and pulmonary inflammation. These are adverse effects that are relevant in ECMO-associated lung injury. Although enzymatic NET degradation by DNase1 represents a potential anti-inflammatory strategy, its anti-inflammatory effects in the lung tissue and on vascular endothelial growth factor (VEGF) signalling have received limited investigation. We used a tissue-architecture-preserving murine lung explant model to characterise inflammation following exposure to activated neutrophils and to determine whether DNase1 attenuates this response without compromising VEGF expression. - Source: PubMed
Publication date: 2026/08/31
Zhang HongKnopf JasminElrod JuliaKlinke MichaelaBoettcher MichaelMartel Richard - Hemophagocytic lymphohistiocytosis (HLH) is associated with high mortality, underscoring the importance of rapid diagnosis and treatment. However, accurate and timely diagnosis is challenging due to its similarities with other acute inflammatory conditions. Traditional diagnostic frameworks rely on fever, lymphadenopathy, cytopenias, hyperferritinemia, hypofibrinogenemia, and related laboratory abnormalities, many of which may reflect either HLH or the underlying condition that triggered or mimics it. Newer diagnostics have emerged that are based on the underlying disease biology, particularly interferon-gamma (IFN-γ)-driven immune activation. C-X-C motif chemokine ligand 9 (CXCL9), a downstream marker of IFN-γ activity, has emerged as a promising adjunctive biomarker for HLH diagnosis, risk stratification, monitoring treatment response, and detection of disease reactivation. This narrative review examines the current evidence surrounding CXCL9 and its role in HLH. - Source: PubMed
Publication date: 2026/08/30
Fusillo Thomas FLiu Johnson M - Skin aging is a major consideration regarding cosmetic skin care. The cosmetic field is seeking new active ingredients able to slow down the appearance of signs of age. Some lichens and more specifically the genus . presents an interest as a source of active molecules because it is already being used in traditional and modern medicines. To better evaluate the potential of as anti-aging skin care, we investigated some key aspects to protect skin from external aggression and to avoid skin alteration, which would exacerbate signs of age. Among them, our results reveal (i) antioxidant capacities; (ii) anti-inflammatory properties on human keratinocytes once stimulated, as shown by a decrease in IL-6, IL-8, CXCL9, CXCL10, and CCL5; (iii) a downregulation of MT1-MMP, which corresponds to decreased tissue remodeling; and (iv) an inhibition of human tyrosinase, which could correct the appearance over time of age-related skin spots. Altogether, these results highlight the potential use of in anti-aging skin care. - Source: PubMed
Publication date: 2026/08/26
Groso AnthonyJabet PaulFan YangHua WangYawen HuMiao GuoDaniellou RichardCollet Guillaume - Immune checkpoint blockade has transformed cancer therapy, yet its efficacy against solid tumors remains constrained by poor T cell infiltration and an immunosuppressive tumor microenvironment. Achieving localized and sustained chemokine signaling without systemic immune toxicity remains a central unmet challenge for cytokine-based immunotherapy. Here, we presented a cryo-engineered bio-depot platform derived from liquid‑nitrogen-treated (LNT) tumor cells for the site-restricted and controlled delivery of protein therapeutics. The cryo-shocked process preserves cellular integrity and protein bioactivity while abolishing pathogenicity of tumor cells, generating a versatile vehicle for therapeutic payloads. Applying this platform, we constructed LNT depots expressing C-X-C motif ligand 9 (CXCL9), which established a persistent chemokine gradient within the lung after intravenous injection, leading to robust T cell recruitment and augmented tumor growth inhibition. Furthermore, we demonstrated the platform adaptability by engineering LNT cells to secrete aPD-1, which significantly prolonged survival in a murine orthotopic lung cancer model. This cryo-engineered depot integrates the structural fidelity of biomaterials with the functional complexity of living systems, offering a generalizable route for personalized protein therapeutics in cancer immunotherapy. - Source: PubMed
Publication date: 2026/09/11
Feng HuihengLiu FengCheng ZeshengZhang HuipengLv WenyueHuang HuanhuanYi XuewenHe KaixinGu ZhenLi Hongjun - The immunosuppressive tumor microenvironment (TME) remains one of the main obstacles that limit responsiveness to immunotherapy. Recently, lipid nanoparticles carrying messenger RNA (mRNA) have emerged as a promising strategy to modulate the immunosuppressive TME, with the ultimate goal of sustaining anticancer immunity of cytotoxic T lymphocytes (CTLs). However, there are challenges with mRNA-based cytokine/chemokine therapies such as the lack of specific targeting, low therapeutic efficacy, and elevated toxicity, raising concerns about their clinical translation. Here, we have developed an antibody-coated lipid nanoparticle (Ab-LNP) delivery system that targets the protein triggering receptor expressed on myeloid cells 2 (TREM2) expressed by tumor-associated macrophages (TAMs). We demonstrate that codelivery of a Toll-like receptor agonist and CXCL9-encoding mRNA encapsulated in our Ab-LNP successfully ameliorates immunosuppression and improves tumor infiltration and activity of CTLs. Further combination with immune checkpoint inhibitors against PD-L1 and CTLA-4 promoted a CTL-favoring immunological environment and durable memory immunity. Our Ab-LNPs targeting TAMs highlight the potential of reprogramming immunosuppressive TME to enhance CTL activity for improved response to cancer immunotherapy. - Source: PubMed
Publication date: 2026/09/11
Chen RuiXu LetaoStaudacher Alexander HWang XingJia RuoxuanFinnie John WWang XiaoyanWhelan Dawn MBrown Michael PZhao Chun-Xia